273 related articles for article (PubMed ID: 9184402)
41. Prolonged heparin administration during clopidogrel treatment in healthy subjects.
Caplain H; D'Honneur G; Cariou R
Semin Thromb Hemost; 1999; 25 Suppl 2():61-4. PubMed ID: 10440426
[TBL] [Abstract][Full Text] [Related]
42. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue.
van Iersel T; Stroissnig H; Giesen P; Wemer J; Wilhelm-Ogunbiyi K
Thromb Haemost; 2011 Feb; 105(2):302-12. PubMed ID: 21103657
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
van Der Auwera P; Platzer E; Xu ZX; Schulz R; Feugeas O; Capdeville R; Edwards DJ
Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
[TBL] [Abstract][Full Text] [Related]
44. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
45. Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit.
Cadroy Y; Caranobe C; Bernat A; Maffrand JP; Sié P; Boneu B
Thromb Haemost; 1987 Aug; 58(2):764-7. PubMed ID: 3672429
[TBL] [Abstract][Full Text] [Related]
46. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
47. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
48. Clinical use of hirudin.
Vogel G; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):113-8. PubMed ID: 2459004
[TBL] [Abstract][Full Text] [Related]
49. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig.
Dickneite G; Nicolay U; Friesen HJ; Reers M
Thromb Haemost; 1998 Jul; 80(1):192-8. PubMed ID: 9684809
[TBL] [Abstract][Full Text] [Related]
50. High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery.
Humphries J; Lattimer C; Smith A; McGuinness CL; Whitton C; Gaffney PJ; Burnand KG
Thromb Res; 1997 Jul; 87(1):123-9. PubMed ID: 9253807
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic studies with recombinant hirudin in dogs.
Nowak G; Markwardt F; Fink E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
[TBL] [Abstract][Full Text] [Related]
52. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
Topol EJ; Bonan R; Jewitt D; Sigwart U; Kakkar VV; Rothman M; de Bono D; Ferguson J; Willerson JT; Strony J
Circulation; 1993 May; 87(5):1622-9. PubMed ID: 8491018
[TBL] [Abstract][Full Text] [Related]
53. A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(4):187-94. PubMed ID: 8872129
[TBL] [Abstract][Full Text] [Related]
54. Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393).
Thürmann P; Harder S; Kirchmaier CM
Eur J Clin Pharmacol; 1995; 48(3-4):241-6. PubMed ID: 7589048
[TBL] [Abstract][Full Text] [Related]
55. DDAVP reduces bleeding during continued hirudin administration in the rabbit.
Bove CM; Casey B; Marder VJ
Thromb Haemost; 1996 Mar; 75(3):471-5. PubMed ID: 8701410
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
57. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
[TBL] [Abstract][Full Text] [Related]
58. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
59. Activated coagulation time in monitoring heparinized dogs.
Green RA
Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
